MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, Ferstl B, Gramatzki M, Rollig C, Weisel K, Jarutat T, Weinelt D, Winderlich M, Peschel C (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Blood American Society of Hematology

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: San Diego, CA US

DOI: 10.1182/blood-2018-153

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Freiburg DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) MorphoSys AG DE Germany (DE) Vienna General Hospital / Allgemeines Krankenhaus der Stadt Wien (AKH) AT Austria (AT) Charité - Universitätsmedizin Berlin DE Germany (DE) Technische Universität München (TUM) DE Germany (DE)

How to cite

APA:

Raab, M.S., Chatterjee, M., Goldschmidt, H., Agis, H., Blau, I., Einsele, H.,... Peschel, C. (2018). MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Raab, Marc S., et al. "MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study." Proceedings of the 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA WASHINGTON: AMER SOC HEMATOLOGY, 2018.

BibTeX: Download